William Blair analyst Sharon Zackfia downgrades Shift Technologies (NASDAQ:SFT) from Outperform to Market Perform.
Legend Biotech’s Cancer Drug, ‘The Most Attractive Product,’ Set For Growth: Analyst
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.